Cargando…
A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alteration...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103868/ https://www.ncbi.nlm.nih.gov/pubmed/25036042 http://dx.doi.org/10.1371/journal.pone.0103050 |
_version_ | 1782327209505062912 |
---|---|
author | Wang, Kendric Shrestha, Raunak Wyatt, Alexander W. Reddy, Anupama Lehár, Joseph Wang, Yuzhou Lapuk, Anna Collins, Colin C. |
author_facet | Wang, Kendric Shrestha, Raunak Wyatt, Alexander W. Reddy, Anupama Lehár, Joseph Wang, Yuzhou Lapuk, Anna Collins, Colin C. |
author_sort | Wang, Kendric |
collection | PubMed |
description | Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alterations of drug targets. However, these alterations are sufficient to explain only a minority of the population, and additional mechanisms of drug resistance or sensitivity are required to explain the remaining spectrum of patient responses to ultimately achieve the goal of precision oncology. We hypothesized that a pan-cancer analysis of in vitro drug sensitivities across numerous cancer lineages will improve the detection of statistical associations and yield more robust and, importantly, recurrent determinants of response. In this study, we developed a statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response. Using the Cancer Cell Line Encyclopaedia (CCLE), a large panel of several hundred cancer cell lines from numerous distinct lineages, we characterized both known and novel mechanisms of response to cytotoxic drugs including inhibitors of Topoisomerase 1 (TOP1; Topotecan, Irinotecan) and targeted therapies including inhibitors of histone deacetylases (HDAC; Panobinostat) and MAP/ERK kinases (MEK; PD-0325901, AZD6244). Notably, our analysis implicated reduced replication and transcriptional rates, as well as deficiency in DNA damage repair genes in resistance to TOP1 inhibitors. The constitutive activation of several signaling pathways including the interferon/STAT-1 pathway was implicated in resistance to the pan-HDAC inhibitor. Finally, a number of dysregulations upstream of MEK were identified as compensatory mechanisms of resistance to the MEK inhibitors. In comparison to alternative pan-cancer analysis strategies, our approach can better elucidate relevant drug response mechanisms. Moreover, the compendium of putative markers and mechanisms identified through our analysis can serve as a foundation for future studies into these drugs. |
format | Online Article Text |
id | pubmed-4103868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41038682014-07-21 A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines Wang, Kendric Shrestha, Raunak Wyatt, Alexander W. Reddy, Anupama Lehár, Joseph Wang, Yuzhou Lapuk, Anna Collins, Colin C. PLoS One Research Article Understanding the heterogeneous drug response of cancer patients is essential to precision oncology. Pioneering genomic analyses of individual cancer subtypes have begun to identify key determinants of resistance, including up-regulation of multi-drug resistance (MDR) genes and mutational alterations of drug targets. However, these alterations are sufficient to explain only a minority of the population, and additional mechanisms of drug resistance or sensitivity are required to explain the remaining spectrum of patient responses to ultimately achieve the goal of precision oncology. We hypothesized that a pan-cancer analysis of in vitro drug sensitivities across numerous cancer lineages will improve the detection of statistical associations and yield more robust and, importantly, recurrent determinants of response. In this study, we developed a statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response. Using the Cancer Cell Line Encyclopaedia (CCLE), a large panel of several hundred cancer cell lines from numerous distinct lineages, we characterized both known and novel mechanisms of response to cytotoxic drugs including inhibitors of Topoisomerase 1 (TOP1; Topotecan, Irinotecan) and targeted therapies including inhibitors of histone deacetylases (HDAC; Panobinostat) and MAP/ERK kinases (MEK; PD-0325901, AZD6244). Notably, our analysis implicated reduced replication and transcriptional rates, as well as deficiency in DNA damage repair genes in resistance to TOP1 inhibitors. The constitutive activation of several signaling pathways including the interferon/STAT-1 pathway was implicated in resistance to the pan-HDAC inhibitor. Finally, a number of dysregulations upstream of MEK were identified as compensatory mechanisms of resistance to the MEK inhibitors. In comparison to alternative pan-cancer analysis strategies, our approach can better elucidate relevant drug response mechanisms. Moreover, the compendium of putative markers and mechanisms identified through our analysis can serve as a foundation for future studies into these drugs. Public Library of Science 2014-07-18 /pmc/articles/PMC4103868/ /pubmed/25036042 http://dx.doi.org/10.1371/journal.pone.0103050 Text en © 2014 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Wang, Kendric Shrestha, Raunak Wyatt, Alexander W. Reddy, Anupama Lehár, Joseph Wang, Yuzhou Lapuk, Anna Collins, Colin C. A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title | A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title_full | A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title_fullStr | A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title_full_unstemmed | A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title_short | A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines |
title_sort | meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103868/ https://www.ncbi.nlm.nih.gov/pubmed/25036042 http://dx.doi.org/10.1371/journal.pone.0103050 |
work_keys_str_mv | AT wangkendric ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT shrestharaunak ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT wyattalexanderw ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT reddyanupama ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT leharjoseph ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT wangyuzhou ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT lapukanna ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT collinscolinc ametaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT wangkendric metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT shrestharaunak metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT wyattalexanderw metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT reddyanupama metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT leharjoseph metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT wangyuzhou metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT lapukanna metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines AT collinscolinc metaanalysisapproachforcharacterizingpancancermechanismsofdrugsensitivityincelllines |